Rabeprazole Sodium for Injection (Aobo Ping®) has been approved for drug registration and will be launched soon!

Rabeprazole Sodium for Injection (Aobo Ping®) has received the New Drug Certificate and the Drug Registration Approval from the NMPA (Drug Approval No.: H20140055). It achieves the goal of early declaration, early production and early market launch, and adds new strength to enhance the market competitiveness of the company.

Rabeprazole Sodium for Injection (Aobo Ping®) is a new generation proton pump inhibitor developed by C&O and it is the first to be launched in China. The product has been applied for national invention patent, and with advanced dosage form, reliable production process, stable product quality, fast onset of action and remarkable clinical efficacy, it fills the gap of no injectable preparation of rabeprazole in China with great market potential. It has taken 6 years since the clinical trial was approved in 2008, and the production has been approved after pharmacological study, pharmacological study, clinical approval, clinical study, production application, material supplement, and production site verification.

The approval for production of Rabeprazole Sodium for Injection (Aobo Ping®) further enriches new product reserve of C&O and provides patients with another safe, reliable and effective drug choice. Together with advantageous products of C&X such as Fushitant®, Lizhixue® and Youmalin®, it becomes a new milestone for C&X in the field of digestion.

Now we sincerely invite agents in all regions of the country to seek common development and to make great achievement together!

Anyone interested can fill in the agent registration form.